METGastric: a phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC)
-
- Shah
- Creator
Journal
-
- ASCO Meeting Abstracts
-
ASCO Meeting Abstracts 33 4012-, 2015